{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":null,"name":"ADAPTela","nct_id":"NCT07242352","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=adaptela-nct07242352. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"ADAPTela","arms":[{"description":"Patients will be treated with elacestrant (ELA) for 5 years. In case further treatment, e.g., CDK4/6 inhibitors, is indicated, ribociclib (RIBO) may be added for 3 years in parallel","label":"Elacestrant upfront (ELA)","type":"EXPERIMENTAL"},{"description":"Patients will be treated with SoC ET for 5-10 years. In case further treatment, e.g., CDK4/6 inhibitors, is indicated, this may be added according to SoC and per investigator´s discretion.","label":"Standard-of-care endocrine treatment (SoC-ET)","type":"ACTIVE_COMPARATOR"}],"collaborators":["Berlin-Chemie Menarini"],"completion_date":{"date":"2033-09-30","type":"ESTIMATED"},"conditions":["Breast Cancer","HR+/HER2- Breast Cancer"],"enrollment":{"count":1520,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Elacestrant","otherNames":["ORSERDU"],"type":"DRUG"},{"name":"Standard-of-care endocrine treatment","otherNames":[],"type":"DRUG"}],"last_update":"2026-08-07","lead_sponsor":"Women's Cancer Study Group GmbH","official_title":"Dynamic Marker - Adjusted Therapy Comparing Adjuvant Elacestrant With Standard Endocrine Treatment in Genomically and/or Clinically High-risk ER+/HER2- Early Breast Cancer (ADAPTela)","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2033-09-30","type":"ESTIMATED"},"primary_outcomes":[{"measure":"5-year invasive disease-free survival (iDFS)","timeFrame":"iDFS 5 years"}],"references":[],"start_date":{"date":"2026-04-29","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Marker - Adjusted Therapy Comparing Adjuvant Elacestrant With Standard Endocrine Treatment in Genomically and/or Clinically High-risk ER+/HER2- eBC","url":"https://clinicaltrials.gov/study/NCT07242352"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/adaptela-nct07242352"}